Short-term effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in age-related maculopathy.
Mursch-Edlmayr Anna Sophie, Luft Nikolaus, Podkowinski Dominika, Ring Michael, Schmetterer Leopold, Bolz Matthias
AI Summary
Aflibercept injection for AMD caused a short-term, IOP-independent reduction in optic nerve head perfusion in the treated eye, but choroidal flow remained stable. This suggests a direct pharmacological effect.
Abstract
Purpose
Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the standard treatment for neovascular age-related macular degeneration (AMD). As VEGF is a physiological key player for regulating retinal vascular tone, questions have been raised whether the application of anti-VEGF could induce alterations in ocular perfusion.
Methods
The study included 20 eyes from 20 Caucasian patients with unilateral neovascular AMD and 20 fellow eyes. All eyes were treated with standard intravitreal injection of aflibercept (IVA). Measurements of blood flow at the optic nerve head (ONH) and the choroid were performed with laser speckle flowgraphy (LSFG). The intraocular pressure (IOP), systolic and diastolic blood pressure, heart rate, mean arterial pressure (MAP) and ocular perfusion pressure (OPP) were analysed. Measurements were performed at baseline and repeated immediately after the injection and 30 and 45 min later.
Results
Mean time between injection of aflibercept and first follow-up was 8:56 ± 4:25 min. The injection led to significant rise in IOP. In the injected eyes, mean blur rate (MBR, i.e. a relative measure of perfusion and the main outcome parameter of LSFG) within the major vessels of the ONH as well as at the entire ONH region decreased significantly (p < 0.001). No change in MBR was observed in the fellow eye. Choroidal blood flow was maintained stable in both eyes.
Conclusion
Intravitreal injection of aflibercept (IVA) led to a short-term reduction in perfusion only in the treated eye. This was independent from IOP, indicating a direct pharmacological effect. No changes in choroidal perfusion were observed during the first 45 min after the injection.
MeSH Terms
Shields Classification
Key Concepts5
Intravitreal injection of aflibercept (IVA) in 20 eyes of 20 Caucasian patients with unilateral neovascular AMD led to a significant rise in intraocular pressure (IOP) immediately after injection.
Intravitreal injection of aflibercept (IVA) in 20 eyes of 20 Caucasian patients with unilateral neovascular AMD resulted in a significant decrease (p < 0.001) in mean blur rate (MBR) within the major vessels of the optic nerve head (ONH) and at the entire ONH region in the injected eyes.
No change in mean blur rate (MBR), a relative measure of perfusion, was observed in the 20 fellow eyes of 20 Caucasian patients with unilateral neovascular AMD after unilateral intravitreal injection of aflibercept (IVA).
Choroidal blood flow was maintained stable in both the injected eyes and the fellow eyes of 20 Caucasian patients with unilateral neovascular AMD during the first 45 minutes after unilateral intravitreal injection of aflibercept (IVA).
Intravitreal injection of aflibercept (IVA) led to a short-term reduction in perfusion only in the treated eye, independent from intraocular pressure, indicating a direct pharmacological effect in 20 eyes of 20 Caucasian patients with unilateral neovascular AMD.
Related Articles5
Intraday repeatability of macular layers measurements in glaucomatous and non-glaucomatous patients using spectral-domain optical coherence tomography.
Observational StudyEffects of Exercise on Optic Nerve and Macular Perfusion in Glaucoma and Normal Subjects.
Clinical TrialStructural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study.
Case SeriesClinically useful smartphone ophthalmic imaging techniques.
ReviewReview of non-invasive intracranial pressure measurement techniques for ophthalmology applications.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.